Comparing the long-term outcomes in chronic coronary syndrome patients with prior ST-segment and non-ST-segment elevation myocardial infarction: findings from the TIGRIS registry
Sibi N Krishnamurthy(University of Miami), Mauricio G. Cohen(Cleveland Clinic Florida), Christopher B. Granger(Clinical Research Institute), Satoshi Yasuda(Tohoku University), Stuart Pocock(London School of Hygiene & Tropical Medicine), Gunnar Brandrup‐Wognsen(AstraZeneca (Sweden)), José Carlos Nicolau(Hospital São Paulo), Shaun G. Goodman(University of Toronto), Prashant Kaul(Piedmont Atlanta Hospital), Dirk Westermann(University Medical Center Freiburg), Karolina Andersson(AstraZeneca (Sweden)), Phillip R. Hunt(AstraZeneca (United States)), Tabassome Simon(Sorbonne Université), David Brieger(The University of Sydney), Ruth Owen(Spanish National Centre for Cardiovascular Research)
Cited by 28
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k